Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 21.4%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 535,000 shares, a decline of 21.4% from the December 31st total of 680,800 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average trading volume of 636,800 shares, the short-interest ratio is presently 0.8 days.

Institutional Investors Weigh In On Tiziana Life Sciences

A hedge fund recently bought a new stake in Tiziana Life Sciences stock. Sanctuary Advisors LLC bought a new stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 907,613 shares of the company’s stock, valued at approximately $864,000. Sanctuary Advisors LLC owned about 0.86% of Tiziana Life Sciences as of its most recent filing with the Securities and Exchange Commission.

Tiziana Life Sciences Trading Down 0.3 %

Shares of NASDAQ:TLSA opened at $0.69 on Friday. Tiziana Life Sciences has a 52-week low of $0.41 and a 52-week high of $1.74. The firm has a fifty day moving average of $0.82 and a 200 day moving average of $0.94.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.